neoMONARCH: CDK inhibition for HR positive, HER negative breast cancer
neoMONARCH: CDK inhibition for HR positive, HER negative breast cancer
Oestrogen deprivation inffective with chemo for HR/HER positive breast cancer
No benefit for adjuvant ibandronate at 3 years in early breast cancer
PARP inhibitory velaparib trialled in BRCA1/2 breast cancer
Matched mutations in the progression of metastatic breast cancer
Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients
Breast cancer screening in the Philippines
PD-1 therapy with eribulin for triple negative MBC
Women experiencing menopause symptoms less likely to adhere to medication
Breast cancer mortality declining globally
Everolimus extends PFS for HR positive, HER2 negative breast cancer
TEAM IIb trial results: Adjuvant ibandronate in early breast cancer